DK0516252T3 - Nanokrystallinske magnetiske jernoxidpartikler til anvendelse ved diagnostik og terapi - Google Patents
Nanokrystallinske magnetiske jernoxidpartikler til anvendelse ved diagnostik og terapiInfo
- Publication number
- DK0516252T3 DK0516252T3 DK92250084.8T DK92250084T DK0516252T3 DK 0516252 T3 DK0516252 T3 DK 0516252T3 DK 92250084 T DK92250084 T DK 92250084T DK 0516252 T3 DK0516252 T3 DK 0516252T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapy
- iron oxide
- magnetic iron
- diagnostics
- oxide particles
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/189—Host-guest complexes, e.g. cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/30—Magnetic particle immunoreagent carriers the magnetic material being dispersed in the polymer composition before their conversion into particulate form
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Ceramic Engineering (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compounds Of Iron (AREA)
- Hard Magnetic Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Soft Magnetic Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4117782A DE4117782C2 (de) | 1991-05-28 | 1991-05-28 | Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0516252T3 true DK0516252T3 (da) | 1997-08-25 |
Family
ID=6432830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92250084.8T DK0516252T3 (da) | 1991-05-28 | 1992-04-13 | Nanokrystallinske magnetiske jernoxidpartikler til anvendelse ved diagnostik og terapi |
Country Status (15)
Country | Link |
---|---|
US (1) | US5427767A (fr) |
EP (1) | EP0516252B1 (fr) |
JP (1) | JP3306810B2 (fr) |
AT (1) | ATE156021T1 (fr) |
AU (1) | AU653220B2 (fr) |
CA (1) | CA2068632C (fr) |
DE (2) | DE4117782C2 (fr) |
DK (1) | DK0516252T3 (fr) |
ES (1) | ES2106134T3 (fr) |
GR (1) | GR3024898T3 (fr) |
IE (1) | IE921595A1 (fr) |
IL (1) | IL101929A (fr) |
NO (1) | NO305105B1 (fr) |
NZ (1) | NZ242669A (fr) |
ZA (1) | ZA923299B (fr) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2785025B2 (ja) * | 1985-03-19 | 1998-08-13 | ランデル・エル・ミルズ | 診断と選択的組織壊死を与える装置 |
US5672334A (en) * | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
DE69207589T2 (de) * | 1992-06-01 | 1996-05-23 | Basf Ag | Anwendung von Dispersionen von magneto-ionischen Partikeln in MRI-Kontrast-Mitteln |
EP0689430B1 (fr) * | 1993-03-17 | 1997-08-13 | Silica Gel Ges.M.B.H | Particules supraparamagnetiques, leur procede de production et leur utilisation |
US5411730A (en) * | 1993-07-20 | 1995-05-02 | Research Corporation Technologies, Inc. | Magnetic microparticles |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
AU2419695A (en) * | 1994-05-12 | 1995-12-05 | Otsuka Pharmaceutical Co., Ltd. | Contrast medium for magnetic resonance imaging |
DE4419256A1 (de) * | 1994-06-01 | 1995-12-07 | Rau Freiherr Von Nagell Helmut | Verwendung von intravenös applizierbarem Eisen zur Therapie von Tumorerkrankungen und/oder Infektionskrankheiten |
DE4421159C1 (de) * | 1994-06-20 | 1995-08-24 | Thomas Bruns | Verwendung von Eisen(III)-oxid (Fe¶2¶O¶3¶) bei Immunschwäche |
DE4428851C2 (de) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
WO1996009840A1 (fr) * | 1994-09-27 | 1996-04-04 | Nycomed Imaging A/S | Agents de contraste |
DE19500665A1 (de) * | 1995-01-12 | 1996-07-18 | Axel Prof Dr Haase | Verfahren zur ortsauflösenden Abbildung eines Bereiches eines biologischen Objektes mit Hilfe elektromagnetischer Strahlen unter Applikation von Kontrastmittel |
DE19508772C2 (de) * | 1995-03-01 | 1998-01-29 | Schering Ag | Verfahren und Verbindungen zur Detektion von Analyten mittels Remanenzmessung und deren Verwendung |
US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
US5695901A (en) * | 1995-12-21 | 1997-12-09 | Colorado School Of Mines | Nano-size magnetic particles for reprographic processes and method of manufacturing the same |
WO1997025073A2 (fr) | 1996-01-10 | 1997-07-17 | Nycomed Imaging A/S | Milieu de contraste |
GB9600427D0 (en) * | 1996-01-10 | 1996-03-13 | Nycomed Imaging As | Contrast media |
DE19600744A1 (de) * | 1996-01-11 | 1997-07-17 | Werner Alois Prof Dipl Kaiser | Magnetische Substanz zur lokalen hyperthermischen Behandlung vorwiegend kleiner Tumore |
US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
US5985312A (en) * | 1996-01-26 | 1999-11-16 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
GB2311138A (en) * | 1996-03-15 | 1997-09-17 | Nycomed Imaging As | ESR-enhanced MRI using magnetic particles as contrast agents |
US20060003163A1 (en) * | 1996-11-16 | 2006-01-05 | Nanomagnetics Limited | Magnetic fluid |
US6713173B2 (en) * | 1996-11-16 | 2004-03-30 | Nanomagnetics Limited | Magnetizable device |
US6986942B1 (en) | 1996-11-16 | 2006-01-17 | Nanomagnetics Limited | Microwave absorbing structure |
WO1999012578A1 (fr) * | 1997-09-10 | 1999-03-18 | Yale University | Dosimetrie par rayonnements avec composes detectables par resonance magnetique |
US6607829B1 (en) * | 1997-11-13 | 2003-08-19 | Massachusetts Institute Of Technology | Tellurium-containing nanocrystalline materials |
US6375634B1 (en) | 1997-11-19 | 2002-04-23 | Oncology Innovations, Inc. | Apparatus and method to encapsulate, kill and remove malignancies, including selectively increasing absorption of x-rays and increasing free-radical damage to residual tumors targeted by ionizing and non-ionizing radiation therapy |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6699724B1 (en) * | 1998-03-11 | 2004-03-02 | Wm. Marsh Rice University | Metal nanoshells for biosensing applications |
US6428811B1 (en) | 1998-03-11 | 2002-08-06 | Wm. Marsh Rice University | Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
US7101575B2 (en) | 1998-03-19 | 2006-09-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly |
ATE501640T1 (de) | 1998-08-12 | 2011-04-15 | Nestle Sa | Inkorporation von exogenen milchsäurebakterien in die mikroflora |
EP1159951A1 (fr) * | 2000-06-02 | 2001-12-05 | Societe Des Produits Nestle S.A. | Utilisation de souches de bacteries d'acide lactique exogenes pour le traitement de maladies correspondant aux Actinomyces naeslundii |
EP0988864A1 (fr) * | 1998-09-23 | 2000-03-29 | Luboldt, Wolfgang, Dr.med. Dipl.-Phys. | Agent de contraste pour la tomographie par résonance magnétique |
US6470220B1 (en) * | 1999-03-29 | 2002-10-22 | The Regents Of The University Of California | Diagnosis and treatment of cancers using in vivo magnetic domains |
US7871597B2 (en) | 1999-04-09 | 2011-01-18 | Amag Pharmaceuticals, Inc. | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
JP4970678B2 (ja) | 1999-06-10 | 2012-07-11 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 多層コーティングによる結晶のカプセル化 |
WO2001037721A2 (fr) * | 1999-11-22 | 2001-05-31 | The Research Foundation Of State University Of New York | Nanoparticules magnetiques pour la therapie selective |
EP1263447B1 (fr) * | 2000-02-08 | 2013-06-26 | Rice University | Nanoparticules optiquement actives destinees a etre utilisees dans des procedes therapeutiques et de diagnostic |
US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
DE60035127T2 (de) * | 2000-03-06 | 2008-02-14 | Dade Behring Marburg Gmbh | Mit polysacchariden beschichtete träger, deren herstellung und verwendung |
AU2001275078A1 (en) | 2000-06-01 | 2001-12-11 | The Board Of Regents For Oklahoma State University | Bioconjugates of nanoparticles as radiopharmaceuticals |
US20050013775A1 (en) * | 2000-06-01 | 2005-01-20 | Kotov Nicholas A. | Bioconjugates of nanoparticles as radiopharmaceuticals |
DE10042023C2 (de) * | 2000-08-08 | 2003-04-10 | Biognostic Ag | Kapseln, die feste Teilchen signalerzeugender Substanzen einkapseln, und deren Verwendung bei Bioassays zum Nachweis von Zielmolekülen in einer Probe |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US7153703B2 (en) * | 2001-05-14 | 2006-12-26 | Board Of Trustees Of The University Of Arkansas N. A. | Synthesis of stable colloidal nanocrystals using organic dendrons |
ITTO20011191A1 (it) * | 2001-12-18 | 2003-06-18 | Itw Ind Components Srl | Dispositivo di servizio per un frigorifero e frigorifero provvisto ditale dispositivo. |
US20030220297A1 (en) | 2002-02-01 | 2003-11-27 | Berstein David L. | Phosphorus-containing compounds and uses thereof |
US20030185757A1 (en) * | 2002-03-27 | 2003-10-02 | Mayk Kresse | Iron-containing nanoparticles with double coating and their use in diagnosis and therapy |
US7249604B1 (en) | 2002-05-10 | 2007-07-31 | Vasmo, Inc. | Medical devices for occlusion of blood flow |
AU2006203585B2 (en) * | 2002-05-31 | 2008-11-06 | Materials Modification, Inc. | A hemostatic composition |
US7670623B2 (en) | 2002-05-31 | 2010-03-02 | Materials Modification, Inc. | Hemostatic composition |
US7273904B2 (en) | 2002-10-03 | 2007-09-25 | The Board Of Trustees Of The University Of Arkansas | Nanocrystals in ligand boxes exhibiting enhanced chemical, photochemical, and thermal stability, and methods of making the same |
GB2393728A (en) * | 2002-10-04 | 2004-04-07 | Nanomagnetics Ltd | Magnetic nanoparticles |
EP1559118B1 (fr) * | 2002-10-30 | 2010-04-14 | Council Of Scientific And Industrial Research | Procede de preparation de particules d'oxyde de fer magnetiques, aciculaires et de taille nanometrique de phase maghemite |
US7560160B2 (en) * | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
US20040109824A1 (en) * | 2002-12-06 | 2004-06-10 | Hinds Kathleen Allison | Particles for imaging cells |
AU2003900335A0 (en) * | 2003-01-22 | 2003-02-13 | Sirtex Medical Limited | Microparticles for selectively targeted hyperthermia |
US7229600B2 (en) * | 2003-01-31 | 2007-06-12 | Nanoproducts Corporation | Nanoparticles of rare earth oxides |
DE10331439B3 (de) | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetische Nanopartikel mit verbesserten Magneteigenschaften |
US7007972B1 (en) | 2003-03-10 | 2006-03-07 | Materials Modification, Inc. | Method and airbag inflation apparatus employing magnetic fluid |
US6982501B1 (en) | 2003-05-19 | 2006-01-03 | Materials Modification, Inc. | Magnetic fluid power generator device and method for generating power |
US7118727B2 (en) * | 2003-06-16 | 2006-10-10 | General Electric Company | Method of making oxide particles |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7344491B1 (en) | 2003-11-26 | 2008-03-18 | Nanobiomagnetics, Inc. | Method and apparatus for improving hearing |
GB0316912D0 (en) | 2003-07-18 | 2003-08-20 | Oxford Instr Superconductivity | Therapeutic treatment |
US7200956B1 (en) | 2003-07-23 | 2007-04-10 | Materials Modification, Inc. | Magnetic fluid cushioning device for a footwear or shoe |
US7396589B2 (en) * | 2003-07-31 | 2008-07-08 | Industrial Technology Research Institute | Core-shell magnetic nanoparticles comprising an inner-transition element |
US7504082B2 (en) * | 2003-07-31 | 2009-03-17 | Industrial Technology Research Institute | Magnetic nanoparticles comprising Gadolinium and method of fabrication |
TW593158B (en) * | 2003-07-31 | 2004-06-21 | Ind Tech Res Inst | Magnetic nanoparticle |
US7448389B1 (en) | 2003-10-10 | 2008-11-11 | Materials Modification, Inc. | Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid |
CN100502948C (zh) * | 2003-10-22 | 2009-06-24 | 复旦大学附属中山医院 | 一种磁性高分子纳米微球载药系统及其制备方法 |
US7393924B2 (en) * | 2004-01-06 | 2008-07-01 | Franco Vitaliano | Smart bio-nanoparticle elements |
WO2005070473A1 (fr) * | 2004-01-15 | 2005-08-04 | Koninklijke Philips Electronics N.V. | Agents de contraste ultrasonore pour l'imagerie moleculaire |
EP1718341A2 (fr) * | 2004-01-20 | 2006-11-08 | Alnis Biosciences, Inc. | Articles comprenant un materiau magnetique et des agents bioactifs |
FR2867180B1 (fr) * | 2004-03-02 | 2006-06-16 | Univ Claude Bernard Lyon | Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation |
DE102004013637A1 (de) | 2004-03-19 | 2005-10-13 | Capsulution Nanoscience Ag | Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln |
WO2006026504A2 (fr) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Formulations orales mucoadhesives de medicaments a permeabilite et solubilite elevees |
EP1642648A1 (fr) * | 2004-09-30 | 2006-04-05 | Roche Diagnostics GmbH | Dispositif et proeédé pour regler la temperature d'un liquide |
JP2008524202A (ja) * | 2004-12-17 | 2008-07-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 分子イメージング及び治療用のターゲティング造影剤又はターゲッティング治療剤 |
US8287583B2 (en) * | 2005-01-10 | 2012-10-16 | Taheri Laduca Llc | Apparatus and method for deploying an implantable device within the body |
US20070150051A1 (en) * | 2005-01-10 | 2007-06-28 | Duke Fiduciary, Llc | Vascular implants and methods of fabricating the same |
US20100041983A9 (en) * | 2005-04-04 | 2010-02-18 | Elisha Rabinovitz | Device and method for pathology detection |
WO2006106507A2 (fr) * | 2005-04-04 | 2006-10-12 | Given Imaging Ltd. | Dispositif et procede de detection de pathologies |
DE102005016873A1 (de) | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
CZ301067B6 (cs) * | 2006-02-24 | 2009-10-29 | Ústav makromolekulární chemie AV CR | Superparamagnetické nanocástice na bázi oxidu železa s modifikovaným povrchem, zpusob jejich prípravy a použití |
EP2023813A4 (fr) * | 2006-05-15 | 2013-03-13 | Dmitri B Kirpotin | Microparticules magnétiques comprenant des substances organiques |
RU2481125C2 (ru) | 2006-12-18 | 2013-05-10 | Колороббия Италия С.П.А. | Магнитные наночастицы для применения при гипертермии, их приготовление и применение в магнитных системах для фармакологического использования |
JP5353004B2 (ja) * | 2007-01-05 | 2013-11-27 | 国立大学法人東京工業大学 | 球形フェライトナノ粒子の製造方法 |
EP2104468A2 (fr) * | 2007-01-08 | 2009-09-30 | Gross, Yossi | Filtre d'implantation in situ |
RU2447901C2 (ru) | 2007-01-21 | 2012-04-20 | Хемотек Аг | Медицинский продукт для лечения обтураций просветов организма и для предупреждения угрожающих повторных обтураций |
EP2114303A4 (fr) | 2007-02-09 | 2012-08-08 | Taheri Laduca Llc | Implants vasculaires et procédés de fabrication desdits implants |
US8512697B2 (en) * | 2007-05-16 | 2013-08-20 | The University Of North Carolina At Chapel Hill | Delivery of micro- and nanoparticles with blood platelets |
DE102007028777A1 (de) * | 2007-06-22 | 2008-12-24 | Carl Zeiss Meditec Ag | Transportvorrichtung |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
FR2922106B1 (fr) * | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
US9943490B2 (en) * | 2007-11-05 | 2018-04-17 | The Trustees Of Princeton University | Composite flash-precipitated nanoparticles |
WO2009075774A2 (fr) * | 2007-12-05 | 2009-06-18 | Massachusetts Institute Of Technology | Particules revêtues de glycosaminoglycane et utilisations |
US8246932B2 (en) * | 2008-03-28 | 2012-08-21 | General Electric Company | Non-radioactive traceable metal isotope-enriched nanoparticles and method of their use for determining biodistribution |
CA2724004C (fr) * | 2008-05-16 | 2016-08-23 | The University Of Sydney | Compositions administrables comportant un materiau particulaire disperse dans un support liquide |
US20110291049A1 (en) * | 2008-06-10 | 2011-12-01 | Board Of Trustees Of The University Of Arkansas | Indium arsenide nanocrystals and methods of making the same |
US11096901B2 (en) | 2009-03-06 | 2021-08-24 | Metaqor Llc | Dynamic bio-nanoparticle platforms |
US11235062B2 (en) * | 2009-03-06 | 2022-02-01 | Metaqor Llc | Dynamic bio-nanoparticle elements |
US20120107229A1 (en) * | 2009-04-15 | 2012-05-03 | Xuefei Huang | Novel nano-probes for molecular imaging and targeted therapy of diseases |
EP3064230B1 (fr) | 2009-07-10 | 2019-04-10 | Boston Scientific Scimed, Inc. | Utilisation de nanocristaux pour un ballonnet de distribution de médicament |
WO2011008393A2 (fr) * | 2009-07-17 | 2011-01-20 | Boston Scientific Scimed, Inc. | Nucléation de ballons dadministration de médicament pour fournir une taille et une densité des cristaux améliorées |
CN102686518B (zh) | 2009-11-20 | 2015-07-29 | 户田工业株式会社 | 磁性氧化铁微粒粉末、含有磁性颗粒的水分散体及其制造方法 |
US20110160645A1 (en) * | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
US9492480B2 (en) * | 2010-04-12 | 2016-11-15 | Ramot At Tel Aviv University Ltd. | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
US10192660B2 (en) * | 2010-07-02 | 2019-01-29 | Sri Lanka Institute of Nanotechnology (Pvt) Ltd. | Process for preparation of nanoparticles from magnetite ore |
US8889211B2 (en) | 2010-09-02 | 2014-11-18 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
US8740872B2 (en) | 2010-10-19 | 2014-06-03 | The Board Of Regents Of The University Of Oklahoma | Magnetically-targeted treatment for cardiac disorders |
US9744235B2 (en) | 2010-10-19 | 2017-08-29 | The Board Of Regents Of The University Of Oklahoma | Treatment of cardiovascular disorders with targeted nanoparticles |
US10398668B2 (en) | 2010-10-19 | 2019-09-03 | The Board Of Regents Of The University Of Oklahoma | Glutamate treatment of cardiovascular disorders |
US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
EP2982652A1 (fr) * | 2014-08-08 | 2016-02-10 | Universität für Bodenkultur Wien | Nanoparticules de type noyau-coqu à coque ultra-dense |
WO2016043680A1 (fr) * | 2014-09-17 | 2016-03-24 | Erol Bülent | Développement de microparticules magnétiques offrant une libération contrôlée de glycosaminoglycane (gag) et son utilisation intravésicale dans des cas de cystite interstitielle |
KR102147451B1 (ko) | 2017-07-21 | 2020-08-24 | 네오-나노메딕스.인크 | 생체 적합적 자기장에서 거대 자기 발열이 가능한 알칼리금속 또는 알칼리토금속이 도핑된 산화철 나노입자 및 그의 제조방법 |
US20200338218A1 (en) * | 2017-11-06 | 2020-10-29 | Yasuhiko Tabata | Hydrogel particle and method for producing same, cell or cell structure each enclosing hydrogel particle therein, method for evaluating activity of cell using hydrogel particle, and use of hydrogel particle as sustained release preparation |
ES2898224T3 (es) | 2018-09-10 | 2022-03-04 | Ivoclar Vivadent Ag | Material dental con partículas magnéticas con apantallamiento de color mejorado |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913521B2 (ja) * | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
US4267234A (en) * | 1978-03-17 | 1981-05-12 | California Institute Of Technology | Polyglutaraldehyde synthesis and protein bonding substrates |
US4247406A (en) * | 1979-04-23 | 1981-01-27 | Widder Kenneth J | Intravascularly-administrable, magnetically-localizable biodegradable carrier |
WO1983001738A1 (fr) * | 1981-11-12 | 1983-05-26 | SCHRÖDER, Ulf | Nanosphere ou nanoparticule a sensibilite magnetique, pouvant etre administree de maniere intravasculaire, son procede de production et son utilisation |
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4731239A (en) * | 1983-01-10 | 1988-03-15 | Gordon Robert T | Method for enhancing NMR imaging; and diagnostic use |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US4767611A (en) * | 1984-07-03 | 1988-08-30 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
PT81498B (pt) * | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
US4758429A (en) * | 1985-11-04 | 1988-07-19 | Gordon Robert T | Method for the treatment of arthritis and inflammatory joint diseases |
AU6621586A (en) * | 1985-11-18 | 1987-06-02 | University Of Texas System, The | Polychelating agents for image and spectral enhancement (and spectral shift) |
US5141739A (en) * | 1986-07-03 | 1992-08-25 | Advanced Magnetics, Inc. | Delivery of x-ray contrast agents using receptor mediated endocytosis |
US4770183A (en) * | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
US5055288A (en) * | 1987-06-26 | 1991-10-08 | Advanced Magnetics, Inc. | Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides |
DE3709851A1 (de) * | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Nmr-diagnostische fluessigkeitszusammensetzungen |
DE3812816A1 (de) * | 1988-04-16 | 1989-11-02 | Lawaczeck Ruediger Dipl Phys P | Verfahren zur solubilisierung von liposomen und/oder biologischer membranen sowie deren verwendung |
US4965007A (en) * | 1988-05-10 | 1990-10-23 | Eastman Kodak Company | Encapsulated superparamagnetic particles |
DE68926708T2 (de) * | 1988-08-04 | 1996-10-31 | Advanced Magnetics Inc | Von einem rezeptor induziertes kontrastmittel für den endocytose-typ mri |
EP0444194B1 (fr) * | 1988-08-19 | 1993-12-22 | Meito Sangyo Kabushiki Kaisha | Agent de thermotherapie |
US5213788A (en) * | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
WO1990003190A1 (fr) * | 1988-09-29 | 1990-04-05 | Ranney David F | Procedes et compositions d'imagerie a resonance magnetique |
FR2652741B1 (fr) * | 1989-10-10 | 1994-03-04 | Laboratoires Care System | Composition antimicrobienne pour application sur la peau, applications comme deodorant corporel et bactericide cutane. |
DK0526503T3 (da) * | 1990-04-10 | 1997-10-27 | Imarx Pharmaceutical Corp | Polymerer som kontrastmedier til magnetisk resonansimagografi |
FR2660864A1 (fr) * | 1990-04-13 | 1991-10-18 | Guerbet Sa | Composition de contraste, procede de preparation de cette composition et application a l'imagerie. |
US5143716A (en) * | 1991-02-01 | 1992-09-01 | Unger Evan C | Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region |
-
1991
- 1991-05-28 DE DE4117782A patent/DE4117782C2/de not_active Expired - Lifetime
-
1992
- 1992-04-13 EP EP92250084A patent/EP0516252B1/fr not_active Expired - Lifetime
- 1992-04-13 AT AT92250084T patent/ATE156021T1/de not_active IP Right Cessation
- 1992-04-13 DE DE59208743T patent/DE59208743D1/de not_active Expired - Fee Related
- 1992-04-13 DK DK92250084.8T patent/DK0516252T3/da active
- 1992-04-13 ES ES92250084T patent/ES2106134T3/es not_active Expired - Lifetime
- 1992-05-05 NO NO921767A patent/NO305105B1/no unknown
- 1992-05-07 ZA ZA923299A patent/ZA923299B/xx unknown
- 1992-05-08 NZ NZ242669A patent/NZ242669A/en unknown
- 1992-05-11 AU AU16184/92A patent/AU653220B2/en not_active Ceased
- 1992-05-13 CA CA002068632A patent/CA2068632C/fr not_active Expired - Fee Related
- 1992-05-13 US US07/882,130 patent/US5427767A/en not_active Expired - Lifetime
- 1992-05-20 IL IL10192992A patent/IL101929A/en not_active IP Right Cessation
- 1992-05-28 JP JP13728592A patent/JP3306810B2/ja not_active Expired - Fee Related
- 1992-07-01 IE IE159592A patent/IE921595A1/en not_active IP Right Cessation
-
1997
- 1997-10-01 GR GR970402545T patent/GR3024898T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE4117782A1 (de) | 1992-12-03 |
NO305105B1 (no) | 1999-04-06 |
JPH07122410A (ja) | 1995-05-12 |
JP3306810B2 (ja) | 2002-07-24 |
ZA923299B (en) | 1992-12-30 |
EP0516252B1 (fr) | 1997-07-30 |
NO921767L (no) | 1992-11-30 |
DE4117782C2 (de) | 1997-07-17 |
EP0516252A2 (fr) | 1992-12-02 |
DE59208743D1 (de) | 1997-09-04 |
CA2068632A1 (fr) | 1992-11-29 |
NO921767D0 (no) | 1992-05-05 |
GR3024898T3 (en) | 1998-01-30 |
IE921595A1 (en) | 1992-12-02 |
CA2068632C (fr) | 2002-10-01 |
EP0516252A3 (en) | 1993-07-28 |
IL101929A0 (en) | 1992-12-30 |
IL101929A (en) | 1994-08-26 |
NZ242669A (en) | 1995-08-28 |
ATE156021T1 (de) | 1997-08-15 |
US5427767A (en) | 1995-06-27 |
AU1618492A (en) | 1992-12-03 |
ES2106134T3 (es) | 1997-11-01 |
AU653220B2 (en) | 1994-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0516252T3 (da) | Nanokrystallinske magnetiske jernoxidpartikler til anvendelse ved diagnostik og terapi | |
DE68908943T2 (de) | Verfahren zur Herstellung von kornorientiertem Elektrostahlblech mit ausgezeichneten magnetischen Eigenschaften und Filmeigenschaften. | |
DE69118680T2 (de) | Russ der einen verbesserten widerstand gegen den laufflächenverschleiss und eine geringere hysterese verleiht und prozess für dessen herstellung | |
BE846849A (fr) | Pigments magnetiques ameliores d'oxyde de fer pour la fabrication de couches magnetiques, | |
DE69020620T2 (de) | Verfahren zum Herstellen von kornorientierten Elektrostahlblechen mit hervorragenden magnetischen Eigenschaften. | |
DE68923544T2 (de) | Magnetische Eisenoxydteilchen und Verfahren zu ihrer Herstellung. | |
DE3751429T2 (de) | Verfahren zum Herstellen kornorientierter Elektrobleche aus Stahl mit magnetischen Eigenschaften. | |
DE68911757D1 (de) | Blättchenförmige Ferritteilchen für magnetische Aufzeichnung und Verfahren zu ihrer Herstellung. | |
EP0165536A3 (en) | Magnetic pigments mainly containing iron, process for their production and their use | |
DE3065058D1 (en) | Process for preparing ferromagnetic acicular iron particles, and their use | |
DE68924454D1 (de) | Aromatischer Imid-Polymer-Film für magnetisches Aufzeichnungsmaterial und Verfahren zu seiner Herstellung. | |
DE3067268D1 (en) | Process for preparing acicular ferromagnetic iron particles, and their use | |
DE69123410D1 (de) | Verfahren zum Herstellen von kornorientierten Siliciumstahlblechen mit verbesserten magnetischen Eigenschaften | |
DE69025417T2 (de) | Verfahren zum Herstellen von kornorientierten Elektrostahlblechen mit hervorragenden magnetischen Eigenschaften | |
DE68918692T2 (de) | Plättchenförmige feine Ferritteilchen für magnetische Aufzeichnung und Verfahren zu ihrer Herstellung. | |
EP0332990A3 (en) | Particulate magnetic hexaferrite pigments containing potassium from precipitated magnetite, process for their production and their use | |
DE3889600D1 (de) | Kornorientierte Elektrobleche mit sehr geringen Eisenverlusten und Verfahren zum Herstellen dieser Bleche. | |
DE58909109D1 (de) | Herstellung von nadelförmigem, im wesentlichen aus eisenhaltigem Chromdioxid bestehenden, ferromagnetischen Material. | |
DE69106293D1 (de) | Nadelförmige ferromagnetische Eisenoxydteilchen und Verfahren zu ihrer Herstellung. | |
IL50893A (en) | Microbiological process for the production of 3a -h-4 -(3'-propanol)-7a -methylhexahydro-1,5-indandione-hemiketal and a new mutant used in this process | |
DE69406499D1 (de) | Kobalt enthaltende Eisenoxidpigmente, Erzeugungsverfahren und diese enthaltendes magnetisches Aufzeichnungsmedium | |
DE69022617D1 (de) | Verfahren zum Herstellen kornorientierter Elektrobleche mit verbesserten magnetischen Eigenschaften. | |
JPS5269893A (en) | Method of treating ferromagnetic chromium dioxide | |
DE68923156T2 (de) | Verfahren zur Herstellung von magnetischen Eisenoxidteilchen für magnetische Aufzeichnung. | |
KE3193A (en) | Asymmetric 1:2 cobalt complexes,their production and use |